Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Timurağaoğlu
Ayşen
A
Department of Hematology, Akdeniz University School of Medicine, Antalya, Turkey. aysentimuragaoglu@yahoo.com
Ozkaynak
Can
C
Tuzuner
Serdar
S
Bostan
Feyzi
F
Undar
Levent
L
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone; D004164:Diphosphonates / Q000009:adverse effects*; D004317:Doxorubicin; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008336:Mandibular Diseases / Q000139:chemically induced / Q000188:drug therapy*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011183:Postoperative Complications / Q000139:chemically induced / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*; D014081:Tooth Extraction / Q000009:adverse effects; D014182:Transplantation, Autologous; D014750:Vincristine; D000077211:Zoledronic Acid
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D011480:Protease Inhibitors; D011719:Pyrazines; D014750:Vincristine; D000069286:Bortezomib; D000077211:Zoledronic Acid; D003907:Dexamethasone; D004317:Doxorubicin